Corey Ritchings

1.5k total citations
25 papers, 258 citations indexed

About

Corey Ritchings is a scholar working on Oncology, Molecular Biology and Infectious Diseases. According to data from OpenAlex, Corey Ritchings has authored 25 papers receiving a total of 258 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 8 papers in Molecular Biology and 4 papers in Infectious Diseases. Recurrent topics in Corey Ritchings's work include Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (10 papers) and Melanoma and MAPK Pathways (7 papers). Corey Ritchings is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), CAR-T cell therapy research (10 papers) and Melanoma and MAPK Pathways (7 papers). Corey Ritchings collaborates with scholars based in United States, United Kingdom and Italy. Corey Ritchings's co-authors include Sumati Rao, Michael B. Atkins, David F. McDermott, Ahmad A. Tarhini, Komal Gupte-Singh, Meredith M. Regan, Lisa Rosenblatt, F. Stephen Hodi, Lillian Werner and Michael A. Postow and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and AIDS.

In The Last Decade

Corey Ritchings

23 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Corey Ritchings United States	9	171	92	47	39	37	25	258
Dominick Leone United States	12	114 0.7×	68 0.7×	69 1.5×	44 1.1×	3 0.1×	21	283
Mingjia Li United States	10	217 1.3×	61 0.7×	102 2.2×	53 1.4×	5 0.1×	30	326
Audrey Sarry France	12	103 0.6×	152 1.7×	43 0.9×	77 2.0×	39 1.1×	27	514
Mary‐Elizabeth M. Percival United States	10	107 0.6×	94 1.0×	9 0.2×	19 0.5×	45 1.2×	53	356
J Maral France	10	101 0.6×	71 0.8×	61 1.3×	133 3.4×	27 0.7×	29	344
Philip Tsau Choong Iau Singapore	8	51 0.3×	92 1.0×	15 0.3×	26 0.7×	26 0.7×	22	247
Vincenzo Federico Italy	10	68 0.4×	41 0.4×	12 0.3×	59 1.5×	18 0.5×	26	247
Dayong Zhu China	7	86 0.5×	30 0.3×	32 0.7×	60 1.5×	6 0.2×	9	176
Andriy Krendyukov Germany	13	270 1.6×	25 0.3×	22 0.5×	181 4.6×	31 0.8×	53	417
Hong Shi China	10	30 0.2×	110 1.2×	14 0.3×	23 0.6×	10 0.3×	27	329

Countries citing papers authored by Corey Ritchings

Since Specialization

Citations

This map shows the geographic impact of Corey Ritchings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Corey Ritchings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Corey Ritchings more than expected).

Fields of papers citing papers by Corey Ritchings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Corey Ritchings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Corey Ritchings. The network helps show where Corey Ritchings may publish in the future.

Co-authorship network of co-authors of Corey Ritchings

This figure shows the co-authorship network connecting the top 25 collaborators of Corey Ritchings. A scholar is included among the top collaborators of Corey Ritchings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Corey Ritchings. Corey Ritchings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Huang, Raymond Y., Gilbert Youssef, Patrick Y. Wen, et al.. (2025). Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMate 204. Journal of Clinical Oncology. 43(10). 1210–1218. 2 indexed citations

Long, Georgina V., Hao Tang, Keyur Desai, et al.. (2025). Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. Journal for ImmunoTherapy of Cancer. 13(7). e012034–e012034.

Long, Georgina V., John M. Kirkwood, Christoph Höeller, et al.. (2023). Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).. Journal of Clinical Oncology. 41(16_suppl). 9504–9504. 8 indexed citations

Hodi, F. Stephen, Vanna Chiarion‐Sileni, René González, et al.. (2023). Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067.. Journal of Clinical Oncology. 41(16_suppl). 9542–9542.

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2023). Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study. Immunotherapy. 16(1). 29–42. 3 indexed citations

Huang, Raymond Y., Patrick Y. Wen, Peter Forsyth, et al.. (2023). 1135P Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204. Annals of Oncology. 34. S680–S681. 1 indexed citations

Long, Georgina V., Keyur Desai, Tania Tang, et al.. (2022). 788O Association of pre-treatment ctDNA with disease recurrence and clinical and translational factors in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy (CheckMate 915). Annals of Oncology. 33. S904–S904. 14 indexed citations

Regan, Meredith M., Charlene Mantia, Lillian Werner, et al.. (2021). Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. Journal for ImmunoTherapy of Cancer. 9(11). e003743–e003743. 26 indexed citations

Regan, Meredith M., Charlene Mantia, Lillian Werner, et al.. (2020). Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067.. Journal of Clinical Oncology. 38(15_suppl). 10043–10043. 2 indexed citations

10.

Kirkwood, John M., Lisa A. Kottschade, Robert R. McWilliams, et al.. (2019). Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE).. Journal of Clinical Oncology. 37(15_suppl). e14144–e14144. 1 indexed citations

11.

Nance, Robin M., Heidi M. Crane, Corey Ritchings, et al.. (2018). Differentiation of Type 1 and Type 2 Myocardial Infarctions Among HIV-Infected Patients Requires Adjudication Due to Overlap in Risk Factors. AIDS Research and Human Retroviruses. 34(11). 916–921. 3 indexed citations

12.

Freeman, Morganna, Alexander N. Shoushtari, Keith A. Betts, et al.. (2018). Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma.. Journal of Clinical Oncology. 36(15_suppl). 9594–9594. 2 indexed citations

13.

Shoushtari, Alexander N., Morganna Freeman, Keith A. Betts, et al.. (2018). Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.. Journal of Clinical Oncology. 36(15_suppl). 9593–9593. 3 indexed citations

14.

Tarhini, Ahmad A., David F. McDermott, Komal Gupte-Singh, et al.. (2018). Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.. Journal of Clinical Oncology. 36(15_suppl). 9538–9538. 2 indexed citations

15.

Regan, Meredith M., Lillian Werner, Ahmad A. Tarhini, et al.. (2018). Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM).. Journal of Clinical Oncology. 36(15_suppl). 9531–9531. 2 indexed citations

16.

LaFleur, Joanne, et al.. (2017). Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 31(15). 2095–2106. 20 indexed citations

17.

Chow, Dominic C., et al.. (2016). Atazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic Review. Infectious Diseases and Therapy. 5(4). 473–489. 12 indexed citations

18.

Rosenblatt, Lisa, et al.. (2016). Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study. BMC Infectious Diseases. 16(1). 492–492. 5 indexed citations

19.

Farr, Amanda M., et al.. (2015). Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting. Journal of Medical Economics. 19(4). 386–396. 5 indexed citations

20.

Farr, Amanda M., et al.. (2014). No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real‐world setting. Journal of the International AIDS Society. 17(4S3). 19538–19538. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact